Giansun Precision Technology Group
001400
Heilongjiang Tianyouwei Electronics
603202
Joy Kie Corporation
300994
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
CN Stock MarketDetailed Quotes
603669 Lionco Pharmaceutical Group
- 4.62
- +0.42+10.00%
Market Closed Apr 24 15:00 CST
3.33BMarket Cap-25.52P/E (TTM)
4.62High4.22Low202.74KlotVolume4.26Open4.20Pre Close91.48MTurnover2.81%Turnover RatioLossP/E (Static)721.24MShares9.5452wk High4.70P/B3.33BFloat Cap3.4552wk Low4.62Limit Up721.24MShs Float20.05Historical High3.78Limit Down9.52%Amplitude2.94Historical Low--Dividend TTM4.51Avg Price115.36KlotAsk--Div YieldTTM100Lot Size78.77KlotBid
Lionco Pharmaceutical Group News
2024 ANNUAL REPORT
2024 Annual Report Summary
Lionco Pharmaceutical Group (603669.SH): Net loss of 0.131 billion yuan in 2024.
On April 18, Glorious Finance announced that Lionco Pharmaceutical Group (603669.SH) released its annual report for 2024, achieving revenue of 0.38 billion yuan during the reporting period, a year-on-year increase of 92.95%; net income attributable to shareholders of the listed company was -0.131 billion yuan; basic EPS was -0.18 yuan.
Lionco Pharmaceutical Group Passes Drug Consistency Evaluation for Anesthesia Adjunct Drug
Lionco Pharmaceutical Group (603669.SH): A subsidiary's injectable Vecuronium Bromide has passed the consistency evaluation for generic drugs.
On April 11, Gelonghui reported that Lionco Pharmaceutical Group (603669.SH) announced that its wholly-owned subsidiary Hainan Meilan Shike Pharmaceutical Co., Ltd. (referred to as "Meilan Shike") recently received the approval notice from the National Medical Products Administration for the "Vecuronium Bromide Injection" (referred to as "the Pharmaceutical"), which has passed the consistency evaluation of quality and efficacy for generic drugs. The Vecuronium Bromide Injection developed by the company is indicated primarily as an adjunct to general anesthesia, used for tracheal intubation during general anesthesia and muscle relaxation during surgery.
Some Shareholders Feeling Restless Over Lionco Pharmaceutical Group Co.,Ltd.'s (SHSE:603669) P/S Ratio
Lionco Pharmaceutical Group Obtains Registration for Naloxone Injection
Lionco Pharmaceutical Group (603669.SH): A subsidiary has obtained the registration certificate for Naloxone Hydrochloride Injection.
On March 11, Glory Exchange announced that Lionco Pharmaceutical Group (603669.SH) has received the "Pharmaceutical Registration Certificate" issued by the National Medical Products Administration for Naloxone Hydrochloride Injection through its wholly-owned subsidiary, Hainan Lionco Pharmaceutical Co., Ltd. The indications for the Naloxone Hydrochloride Injection developed by the company are: suitable for the complete or partial reversal of opioid depression caused by natural and synthetic opioids (including propxyphene, methadone, and certain agonist-antagonist analgesics: nalbuphine, pentazocine, buprenorphine, and cyclazocine), including respiratory depression. It is suitable for diagnosing suspected or known acute opioid overdose. It can be used as an adjunctive treatment for symptoms.
Lingkang Pharmaceutical: 2024 Annual Results Forecast
2024 Annual Results Forecast
Lionco Pharmaceutical Group (603669.SH): It is expected to have a net loss of approximately 0.12 billion yuan in 2024.
On January 16, GLONGHUI reported that Lionco Pharmaceutical Group (603669.SH) announced, based on preliminary calculations from the company's financial department, it is expected that the net income attributable to the parent company for the year 2024 will be around -120 million yuan, which represents a reduction in losses of approximately 20.79% compared to the same period last year (statutory disclosed data). It is expected that the net income attributable to the parent company, excluding non-recurring gains and losses, will be around -165 million yuan, reflecting a reduction in losses of about 9.26% compared to the same period last year (statutory disclosed data). It is expected that the revenue for the year 2024 will be around 380 million yuan, compared to the same period last year (law.
Private Companies Among Lionco Pharmaceutical Group Co.,Ltd.'s (SHSE:603669) Largest Shareholders, Saw Gain in Holdings Value After Stock Jumped 11% Last Week
Lionco Pharmaceutical Group (603669.SH): Subsidiary participates in the national pharmaceutical centralized procurement and plans to be selected.
On December 13, Gelonghui reported that Lionco Pharmaceutical Group (603669.SH) announced that its wholly-owned subsidiary Hainan Lionco Pharmaceutical Co., Ltd. participated in the tenth batch of national centralized procurement organized by the National Organization for Pharmaceutical Joint Procurement Office (referred to as the 'Joint Procurement Office'). According to the public announcement of the proposed selection results of national centralized procurement released by the Joint Procurement Office, Lionco Pharmaceutical's product, injectable ceftazidime sodium, is proposed to be selected for this centralized procurement. The sales revenue of injectable ceftazidime sodium from Lionco Pharmaceutical's wholly-owned subsidiary in 2023 amounted to 0 million yuan, accounting for 0% of the company's revenue for the year 2023; sales for the first three quarters of 2024.
Revenues Not Telling The Story For Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) After Shares Rise 29%
Is Lionco Pharmaceutical GroupLtd (SHSE:603669) Using Debt Sensibly?
Company Report for the Third Quarter of 2024 (after correction)
Announcement on additional information to the 2024 Third Quarter Report
lionco pharmaceutical group (603669.SH) subsidiary cephalosporin sodium for injection passed the generic drug consistency evaluation.
Lionco Pharmaceutical Group (603669.SH) announced that its wholly-owned subsidiary Hainan Lionco Pharmaceutical Co., Ltd. (referred to as "...
Lingkang Pharmaceutical: Third Quarter Report 2024
Third Quarter Report 2024